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Abstract
Sporadic inclusion body myositis (IBM) is the most common primary myopathy in the elderly, but its pathoetiology
is still unclear. Perturbed myocellular calcium (Ca2+) homeostasis can exacerbate many of the factors proposed to
mediate muscle degeneration in IBM, such as mitochondrial dysfunction, protein aggregation, and endoplasmic
reticulum stress. Ca2+ dysregulation may plausibly be initiated in IBM by immune-mediated membrane damage
and/or abnormally accumulating proteins, but no studies to date have investigated Ca2+ regulation in IBM patients.
We first investigated protein expression via immunoblot in muscle biopsies from IBM, dermatomyositis, and
non-myositis control patients, identifying several differentially expressed Ca2+-regulatory proteins in IBM. Next,
we investigated the Ca2+-signaling transcriptome by RNA-seq, finding 54 of 183 (29.5%) genes from an unbiased
list differentially expressed in IBM vs. controls. Using an established statistical approach to relate genes with
causal transcription networks, Ca2+ abundance was considered a significant upstream regulator of observed
whole-transcriptome changes. Post-hoc analyses of Ca2+-regulatory mRNA and protein data indicated a lower
protein to transcript ratio in IBM vs. controls, which we hypothesized may relate to increased Ca2+-dependent
proteolysis and decreased protein translation. Supporting this hypothesis, we observed robust (4-fold) elevation
in the autolytic activation of a Ca2+-activated protease, calpain-1, as well as increased signaling for translational
attenuation (eIF2α phosphorylation) downstream of the unfolded protein response. Finally, in IBM samples we
observed mRNA and protein under-expression of calpain-3, the skeletal muscle-specific calpain, which broadly
supports proper Ca2+ homeostasis. Together, these data provide novel insight into mechanisms by which intracellular
Ca2+ regulation is perturbed in IBM and offer evidence of pathological downstream effects.
Keywords: Myositis, Inclusion body, Muscular diseases, Calcium, Calpain, Unfolded protein response
Introduction
Sporadic inclusion body myositis (IBM) is the most com-
mon acquired myopathy in the elderly [22]. Phenotypic
characteristics of IBM patients include both proximal and
distal weakness and atrophy, typically worst in the knee
extensors and finger flexors [35]. Histologically, IBM bi-
opsies often display cytoplasmic protein “inclusions,”
rimmed vacuoles, mitochondrial abnormalities, increased
MHC type I expression, and infiltrating CD8+ T cells [22].
The molecular pathogenesis of IBM remains unclear and
is controversial, but likely involves both inflammatory and
myodegenerative processes [5, 14]. However, unlike in
other inflammatory myopathies (i.e. dermatomyositis
(DM), polymyositis, and immune-mediated necrotizing
myopathies), immunosuppressive therapy is not beneficial
in the vast majority of IBM cases, suggesting that disease
progression occurs independent of the inflammatory re-
sponse [5]. Currently, there are no widely-accepted animal
models of IBM that recapitulate human disease. A better
mechanistic understanding of myodegeneration in IBM
may allow development of relevant animal models and
identification of new avenues for therapy.
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In healthy skeletal muscle fibers, low resting intracel-
lular calcium (Ca2+) concentrations (~50nM) are tightly
maintained by an array of Ca2+ sensors, channels, trans-
porters, and buffers [9]. When this regulation is
perturbed, prolonged cytosolic Ca2+ elevations can cause
various downstream myodegenerative phenomena,
including two strongly associated with IBM pathogenesis
[8]. The most prominent mechanistic hypothesis for
IBM myodegeneration implicates abnormal proteostasis,
as many proteins associated with neurodegenerative
disease (e.g. TDP-43, p62, amyloid-β, and αβ-crystallin)
are reported to aggregate in the cytosol of IBM-affected
myofibers [2, 12, 23]. Ca2+ dysregulation contributes to
abnormal proteostasis by promoting mitochondrial re-
active oxygen species (ROS) production and perturbing
protein folding in the endoplasmic reticulum (ER) lumen
[18, 31]. Additionally, activation of Ca2+-dependent pro-
teases downstream of Ca2+ dysregulation may cause
TDP-43 cytosolic mislocalization (a specific finding in
IBM vs. other inflammatory myopathies) [57]. Another
factor proposed to cause myodegeneration in IBM is
mitochondrial dysfunction; accumulation of mtDNA de-
letions, ultrastructural abnormalities, loss of oxidative
phosphorylation enzyme activity, and abnormal mito-
phagy have been reported in IBM muscle [31, 48]. As
with proteostasis, Ca2+ dyshomeostasis is closely linked
with mitochondrial dysfunction. Excessive Ca2+ uptake
by the mitochondria can stimulate ROS production,
initiate formation of the permeability transition pore,
and diminish the inner mitochondrial membrane poten-
tial critical for oxidative phosphorylation [7, 13, 31].
The direct link between Ca2+ dysregulation, abnormal
proteostasis, and mitochondrial dysfunction makes Ca2+
regulation a phenomenon of potential pathological
significance in IBM. Although Ca2+ regulation has not
yet been investigated in human cases of IBM, data exist
suggesting that some proteins associated with IBM can
mediate an insult to Ca2+ homeostasis [1, 11, 34, 46].
Additionally, abnormal Ca2+ regulation may plausibly
stem from membrane pores and osmotic stress, as clonal
cytotoxic T-cells (expressing membranolytic enzymes)
have been reported in IBM and may have a particularly
aggressive phenotype [16, 20, 44]. Given the plausibility
of an insult to Ca2+ regulation in IBM, we hypothesized
that human cases of IBM would display downstream
gene and protein-level evidence of alterations consistent
with Ca2+ dysregulation. In this study, we compared
muscle biopsies from IBM patients with those of DM
(an inflammatory myopathy without prominent degene-
rative characteristics) patients and non-myositis con-
trols, investigating a panel of Ca2+-regulatory proteins as
well as the Ca2+ signaling transcriptomic pathway. To
explain observed alterations, we investigated proteolytic
activation of ubiquitously expressed calpain-1, expression
of the skeletal muscle specific calpain-3, and ER stress-
induced translational attenuation.
Materials and methods
Subjects and tissue samples
All procedures were completed under Institutional Review
Board (IRB) approved protocols of the University of
Maryland and Johns Hopkins University School of
Medicine. Patients from the Johns Hopkins Myositis
Center consented to use of their snap-frozen, rectus
femoris biopsy samples for IRB-approved research pur-
poses. Patients in the IBM group met ENMC 2011 criteria
for clinically defined IBM whereas patients in the DM
group met Bohan and Peter criteria [6, 21, 47] (Table 1).
Patients in the non-myositis control group (labeled CON
in figures) were referred to the Johns Hopkins Myositis
Center for suspected myopathy, where they were clinic-
ally normal or mild in presentation and had normal
biopsies with no pathologic findings suggestive of an
inflammatory myopathy.
Table 1 Demographic information and serum creatine kinase levels for patients included in this study
Immunoblots RNA-sequencing
CON (n = 5) DM (n = 4) IBM (n = 7) CON (n = 7) IBM (n = 9)
Age at Biopsy (years)
Mean (SD) 62 (4.2) 64.5 (5.8) 65.6 (7.0) 43 (11.2) 62.3 (11.1)
Ethnicity
Caucasian (%) 4 (80) 4 (100) 6 (85.7) 6 (85.7) 7 (77.8)
African American (%) 1 (20) 0 1 (14.3) 0 1 (11.1)
Asian (%) 0 0 0 1 (14.2) 1 (11.1)
Sex
Male (%) 4 (80) 4 (100) 6 (85.7) 3 (42.9) 4 (14.4)
Female (%) 1 (20) 0 1 (14.3) 4 (57.1) 5 (55.6)
Serum Creatine Kinase (U/L)
Mean (SD) 543 (569) 451 (776) 763 (659) 198 (221.8) 700 (630)
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Analysis of protein expression
Samples were prepared as previously described [10].
Briefly, rectus femoris muscle biopsy samples were trans-
ferred from liquid nitrogen directly to a tube containing
chilled RIPA buffer (0.15 M NaCl, 0.01 M Tris–HCl pH 8,
0.005 M EDTA, 0.5% Sodium Deoxycholate, 0.1% SDS, 1%
Triton-X100) and 1 cOmplete™ protease inhibitor cocktail
(Sigma-Aldrich) on ice. Biopsies were minced with sterile
lab scissors and further homogenized with a Polytron ma-
chine. Homogenates were spun at 4 °C for 10 minutes at
14000 rpm (20000 RCF) and soluble protein extracted.
Lysate protein concentration was determined via bicinch-
oninic acid assay (Thermo Fisher). Samples were prepared
to have equal total protein concentration and were ali-
quoted for storage at −80 °C until analysis. Samples for
analysis were solubilized in loading buffer and heated at
100 °C for 5 minutes, and stored at 4 °C until subse-
quent analyses. Antibodies and concentrations used
were: anti-SERCA1 1:1000 (Cell Signaling Technology
#12293s), anti-SERCA2 1:1000 (Thermo Fischer
#9580s), anti-MCU 1:2000 (Cell Signaling Technology
#14997), anti-CSQ 1:2500 (Thermo Fischer PA1-913),
anti-RyR1 1:500 (Thermo Fischer MA3-925), anti--
DHPR1α 1:2000 (Thermo Fischer MA3-920), anti-
STIM1 1:1000 (BosterBio PB9406), anti-LETM1 1:2000
(Santa Cruz sc-271234), anti-Grp78/BiP 1:1000 (BD
Transduction 3177p), anti-CHOP 1:1000 (Cell Signaling
Technology 2895s), anti-eIF2α 1:2000 (Cell Signaling
Technology 9722s), anti-P-eIF2α 1:1000 (Cell Signaling
Technology 9721s), anti-calpain-1 1:1000 (Thermo Fischer
MA1-12434), anti-calpain-3 (Santa Cruz sc-365277),
anti-β-actin 1:1000 (Santa Cruz #47778), and anti-
vinculin 1:10000 (Sigma-Aldrich V9131). Antigen-antibody
complexes were visualized after incubation with Western
Clarity ECL (Bio-Rad) and analyzed using either the
Bio-Rad Image Lab™ software or ImageStudioLite™. Equal
protein loading was confirmed with total protein staining,
as previously discussed [10], as well as with probes for
β-actin or vinculin.
Analysis of mRNA expression and protein to transcript
ratios
Samples for RNA sequencing were prepared using a
standard TRIzol protocol. Briefly, biopsies were homoge-
nized in TRIzol using 1.4 mm ceramic bead low-binding
tubes. After phenol-chloroform extraction, RNA was
purified and treated with DNase using the RNeasy Mini
Kit (Qiagen). Concentration and quality of the resulting
RNA was assessed using standard NanoDrop and TapeS-
tation protocols, respectively. Samples were included in
analysis with a RNA quality (RINe) value of 7 or higher.
Paired-end libraries were prepared using 50 ng of input
RNA with the NeoPrep™ system according to the TruSeq™
Stranded mRNA Library Prep protocol (Illumina) and
subsequently analyzed using the Illumina HiSeq 2500 ma-
chine. Reads were demultiplexed using Casava 1.8.2 and
the quality of the resulting fastq files was tested using
FastQC 0.11.2. There was no need to mask or trim the
reads, as all nucleotide positions had a median Phred
score over 30. Reads were aligned to the reference genome
(hg19) using Tophat 2.0.134. The fragments per kilobase
of exon per million fragments mapped (FPKM) values of
each gene in each group were compared using Cuffdiff
(Cufflinks 2.2.1) [52] and the graphical analysis was per-
formed using CummeRbund 2.12.1 [53]. Pathway analysis
and upstream regulator analysis was performed with
Ingenuity® Pathway Analysis (IPA) software, using stand-
ard settings [26]. Post-hoc analysis was performed to com-
pare protein expression relative to mRNA levels; mean
protein levels (AU; via densitometry of immunoblot) for
the studied Ca2+-regulatory proteins were divided by
FPKM values for each protein. Group means for IBM and
controls were compared using Student’s t test.
Assessment of calpain-1 autolysis
Calpain-1 autolysis was assessed by quantifying full-length
(80 kDa) calpain-1 band densitometry, in arbitrary units,
as well as cleaved (78 and 76 kDa) isoforms using a
method previously described [36]. Briefly, calpain-1 au-
tolysis is a proxy for enzymatic activity [3], and is defined
as the percentage of total calpain-1 in its cleaved isoforms.
To facilitate distinction of each individual band, biopsy
samples homogenized in the aforementioned RIPA lysis
buffer were electrophoresed on lower acrylamide
percentage (6-8%) gels over a longer duration (2.5 hours
at 120 V).
Assessment of unfolded protein response activation and
translational attenuation
To induce downstream effectors of the UPR, an ER
stress sensor, Ire1α, facilitates alternative splicing of X-
Box Binding Protein 1 (XBP1) mRNA [40]. We quanti-
fied XBP1 splicing and overall XBP1 mRNA expression
from RNA-seq data. We also investigated protein ex-
pression of Grp78/BiP and C/EBP homologous protein
(CHOP), effector molecules of the UPR that are upregu-
lated with ER stress [40]. To quantify translational
attenuation signaling, we assessed the validated ratio of
phosphorylated eukaryotic initiation factor (eIF2α) to
total eIF2α [40].
Data analysis and statistics
All statistical tests and parameters were established, and
all experimental data collection and analysis were per-
formed, while the responsible investigators were blind to
sample identity. All protein expression values, as quanti-
fied by densitometry, were expressed as fold change vs.
controls with error bars representing standard error of
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the mean (SEM). Student's t test, using pre-specified
parameters, was used as the primary moderator of
significant differences between experimental groups for
immunoblots. Where appropriate, false discovery rate
(q-value) was used to adjust the significance of analyses
for multiple comparisons [4].
Results
Ca2+-regulatory protein expression is altered in IBM
We used immunoblotting to investigate the expression
of a pre-specified panel of Ca2+-regulatory proteins that
have been implicated in skeletal myopathy (Fig. 1). The
sarco/endoplasmic reticulum Ca2+ ATPase (SERCA)
proteins, SERCA1 and SERCA2a, are critical intracellular
Ca2+ buffering proteins in fast and slow skeletal muscle,
respectively. The SERCA proteins function to actively
transport Ca2+ from cytosol to the SR lumen and are sub-
ject to cytosolic Ca2+ concentration-dependent proteolysis
by calpains [49]. Compared with controls, SERCA1 pro-
tein was reduced 64% in IBM (p < 0.01) and 57% in DM
(p < 0.01). SERCA2 was reduced 51% in IBM compared to
controls (p < 0.05) and showed a non-significant trend to-
ward reduction compared to DM (35% decrease, p = 0.07).
Calsequestrin (CSQ) has an important Ca2+-binding func-
tion in the SR, serving as a buffer to reduce effective Ca2+
concentration in the SR lumen and augment SERCA func-
tion [37, 42]. CSQ expression levels were 34% lower in
muscles from IBM patients compared to muscles from
both controls (p < 0.05) and DM (p = 0.05). The mitochon-
drial Ca2+ uniporter (MCU) is an inner mitochondrial
membrane complex that buffers the cytoplasmic concen-
tration of Ca2+ by facilitating entry of Ca2+ into the mito-
chondrial matrix. We detected a 75% increase in MCU
expression in IBM vs. both controls (p < 0.01) and DM
(p < 0.01). The skeletal muscle RyR1 is the primary Ca2+
release channel of the SR, has altered Ca2+ gating after
exposure to ROS, and is dynamically regulated by cal-
pain cleavage [15, 45]. We observed 60% lower levels of
RyR1 in IBM vs controls (p < 0.05), but no difference
between IBM and DM (p = 0.12). The DHPR is an
L-type sarcolemmal Ca2+ channel that allows Ca2+ influx
from the extracellular space and regulates RyR1-dependent
Ca2+ release during excitation-contraction coupling. DHPR
expression was decreased in both IBM (p < 0.05) and DM
(p < 0.05) vs. controls, but did not significantly differ
between IBM and DM (p = 0.17). We did not detect any
differences between groups in expression of leucine zipper
and EF-hand containing transmembrane protein (LETM1),
a mitochondrial Ca2+/H+ antiporter, or stromal interaction
molecule 1 (STIM1), an SR protein that acts a sensor of
Ca2+ levels within the SR lumen (all p > 0.10). Together,
these observed alterations are consistent with elevated
basal Ca2+ levels in IBM myofibers, which we predicted
would also result in transcriptomic alterations.
a b
Fig. 1 Altered Ca2+-regulatory protein expression in IBM. a Protein levels of pre-specified panel of proteins, as assessed by immunoblot, expressed
as mean + SEM. N = 5, 4, and 7 for non-myositis controls (CON), DM, and IBM, respectively. b Representative immunoblots. *P < 0.05 vs CON;
†P < 0.05 vs DM; ℥P = 0.07 vs DM
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Differential Ca2+ signaling gene expression and reduced
protein per transcript in IBM
Paired-end RNA-sequencing analysis of IBM and non-
myositis control samples was performed on RNA iso-
lated from muscle biopsies. 183 genes, selected from the
KEGG Ca2+ signaling pathway (an unbiased gene list),
were investigated from whole-transcriptome data. From
these 183 genes, 54 (29.5%) were differentially expressed
(false discovery rate (q) < 0.05; Fig. 2a). A relevant gene
of interest that was not included in the KEGG signaling
pathway, PVALB, encodes parvalbumin, a cytosolic Ca2+
buffer. PVALB mRNA was increased 2.7-fold in IBM
samples (q < 0.001). Dysregulation of the canonical Ca2+
signaling pathway, as assessed using Ingenuity Pathway
Analysis, was significant (q < 0.01). Using an established
statistical approach to relate genes with causal regulatory
networks [26], Ca2+ abundance was a significant up-
stream regulator of the observed whole-transcriptome
changes (q < 0.01, activation z score = 2.734). Full Ca2+
signaling gene list data, with read quantity, fold change,
and q values, are available in Additional file 1: Electronic
Resource 1. Interestingly, of the six proteins we found to
be differentially expressed in IBM vs. controls via
immunoblot, none were significantly altered at the mRNA
level (all q > 0.10; Fig. 2c). Indeed, when averaging the pro-
tein to transcript ratio of the Ca2+-regulatory proteins
assessed in this study, IBM had significantly less (p < 0.05)
protein per transcript than control biopsies (Fig. 2d), im-
plicating post-transcriptional down-regulation of these
proteins via increased degradation or reduced translation.
Altered levels of Ca2+-activated proteases in IBM
Since our data implicated cytosolic Ca2+ elevations in
IBM, we hypothesized that Ca2+-activated proteolysis
may contribute to the decreased protein to transcript ra-
tio amongst Ca2+-regulatory proteins. Amongst other
functions, the ubiquitously expressed calpain-1 is known
to irreversibly cleave SR Ca2+ regulatory proteins [45, 49].
Calpain-1 autolyzes at physiologically high (μM) concen-
trations of Ca2+, forming active/proteolytic 78 and 76 kDa
isoforms that can be quantified via immunoblot [36, 50].
Total calpain-1 protein expression was not different
between groups (p > 0.10; data not shown). However, in
IBM samples, we detected prominent 78 and 76 kDa
bands, reflecting proteolytically active isoforms (Fig. 3a).
Chemiluminescent quantification of these cleaved forms,
a b
c d
Fig. 2 Ca2+ signaling transcriptome perturbations in IBM and related post-hoc analyses. a Heat map of differentially expressed (q < 0.05) genes in
IBM (n= 9) versus controls (CON; n= 7) from the KEGG Ca2+ signaling pathway. b Representative network image showing the relationship between Ca2+
signaling and transcriptomic regulators; Ca2+ abundance was considered a significant (q < 0.01) upstream regulator of observed changes. Orange nodes
indicate activation consistent with Ca2+ abundance. c Expression of mRNA (FPKM) for the genes encoding previously immunoblotted Ca2+-regulatory
proteins, demonstrating no significant (q < 0.05) changes in expression. d Reduced protein to transcript ratio amongst Ca2+-regulatory proteins in IBM,
expressed as mean + SEM. *P< 0.05 versus CON
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divided by total calpain-1, shows an approximate 4-fold
elevation in calpain-1 autolysis in IBM vs. controls (p <
0.01) and DM (p < 0.05) (Fig. 3b). Unlike calpain-1, the
skeletal muscle specific calpain-3 does not cleave Ca2
+-regulatory proteins. Alternatively, calpain-3 appears to
broadly support cellular Ca2+ homeostasis by preventing
degradation of SERCA proteins, supporting RyR1 func-
tion, and stabilizing the sarcomeric triad [17, 39, 51]. Of
interest, loss-of-function mutations in calpain-3 are
known to cause limb girdle muscular dystrophy type 2a
(LGMD2a; also called calpainopathy) [27], and transgenic
reduction of calpain-3 in mice causes severe Ca2+ dysregu-
lation [54]. At the mRNA level, expression of calpain-3
was ~50% lower in IBM samples vs. controls (q < 0.05).
At the protein level, native calpain-3 was reduced 66%
in IBM vs. controls (p < 0.01) and 50% vs. DM (p <
0.05). DM and controls did not significantly differ in
calpain-3 protein expression (p = 0.22).
Translational attenuation downstream of the unfolded
protein response in IBM
In addition to proteolysis, we hypothesized that altered
translation might play a role in the observed decrease in
protein to transcript ratio for Ca2+-regulatory proteins.
Protein accumulation and Ca2+ dysregulation activate
ER stress signaling and the UPR to restore normal pro-
teostasis. Initiated by alternative splicing of XBP1, the
UPR up-regulates effector molecules (e.g. chaperone
proteins) but broadly halts protein translation through
phosphorylation of eIF2α. Compared with controls,
XBP1 mRNA was upregulated and preferentially spliced
to its UPR effector form in IBM (p < 0.05; Fig. 4a, b).
IBM-specific over-expression of two UPR effectors,
Grp78/BiP (a heat-shock protein) and CHOP (a down-
stream pro-apoptotic transcription factor) further sup-
ported the evidence for UPR activation at the protein
level (p < 0.01; Fig. 4c, d). Total eIF2α expression was
not different between groups, but relative phosphoryl-
ation of eIF2α was ~2.5-fold elevated in IBM samples
compared with controls (p < 0.05) and DM (p < 0.01)
(Fig. 4d, e). These data suggest that the UPR is activated
in IBM, leading to reduced protein translation.
Discussion
Ca2+ is a ubiquitous second messenger in skeletal
muscle, regulating processes as varied as secretion,
contraction, and apoptosis. In healthy myofibers, intra-
cellular Ca2+ concentration is maintained in a tight
homeostasis by various Ca2+-regulatory proteins which
function as ion sensors, channels, transporters, and
buffers. Diminished Ca2+ regulation, typically resulting
in pathologically high levels of cytosolic Ca2+, plays a
pathogenic role in several neurodegenerative and neuro-
muscular diseases and has many upstream causes [54,
56]. For example, pathogenic Ca2+ dysregulation is
linked with RyR1 alterations in Alzheimer’s disease [15],
mutant protein-induced mitochondrial dysfunction in





Fig. 3 Calpain-1 autolysis and calpain-3 reduction in IBM. a Representative immunoblot demonstrating prominent autolysis of 80 kDa native
calpain-1 to proteolytically active calpain isoforms. b Quantification of 78 and 76 kDa calpain-1 band areas divided by total calpain-1. c Representative
western blot of native calpain-3 expression. d Quantified expression of native calpain-3 protein levels. e Transcript expression of CAPN3 gene as
determined by RNA-seq. Graphed data expressed as mean + SEM. N of 5, 4, and 7 for non-myositis controls (CON), DM, and IBM, respectively; *P < 0.05
vs CON; †P < 0.05 vs DM
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dystrophinopathies [54]. Pathologic downstream effects
of prolonged Ca2+ dysregulation include mitochondrial
dysfunction and abnormal proteostasis, two likely con-
tributors to myodegeneration in IBM [31]. In this inves-
tigation, we report alterations in several proteins and
genes associated with Ca2+ regulation in IBM muscle,
associate these changes with Ca2+ overabundance, and
identify potential mechanisms contributing to Ca2+
dysregulation. This novel study of Ca2+ regulation in
myositis patients strongly supports the hypothesis that
Ca2+ dysregulation is present in and pathologically
relevant to IBM.
Compared with control and DM muscle biopsies, IBM
samples had decreased SERCA1, SERCA2, and CSQ
protein and increased MCU protein, supporting mecha-
nisms by which both cytosolic and mitochondrial Ca2+
concentrations are likely elevated. Compared with con-
trols, both DM and IBM had reduced levels of RyR1 and
DHPR protein, which may reflect a non-specific change
associated with muscle damage or inflammation. Of
note, reduced protein levels of SERCA1, the fast-twitch
SERCA isoform, was previously reported in a proteomic
study of IBM that describes broad expression reductions
in fast twitch proteins [43]. Interestingly, in this study,
the 30 most reduced proteins in IBM (by fold-change)
included SERCA1 (#11, 0.53-fold) and CSQ (#15, 0.58-
fold) [43]. We observed similar decreases in SERCA1
and CSQ; however, the reduction in SERCA expression
in our IBM patients did not predominantly affect the
fast isoform, as the SERCA1 to SERCA2 ratio was un-
changed between groups (Additional file 2: Electronic
Resource 2). Altered expression of Ca2+-regulatory pro-
teins have not been reported in the three other IBM
proteomic studies to date, although these studies each
report alterations in only 29 proteins or fewer [24, 29,
30], likely reflecting limitations of the 2-D gel electro-
phoresis approach to detect differential protein expres-
sion in muscle biopsies.
Prior studies have investigated the IBM transcriptome,
although no study to our knowledge has reported on alter-
ations in the Ca2+ pathway. Primarily, these studies use
microarrays to screen for genes with high comparative
a b c
d e
Fig. 4 Activation of the UPR and downstream translational attenuation in IBM. a XBP1 transcript levels (RNA-seq). b Isoform-specific expression of
ubiquitous (U) and spliced (S) XBP1 transcript (RNA-seq). c Representative immunoblots of UPR effector molecules d Quantification of UPR effector
protein levels. e Relative phosphorylation of eIF2α, a marker of translational attenuation. Graphed data expressed as mean + SEM. N of 5, 4, and 7
for non-myositis controls (CON), DM, and IBM, respectively; *P < 0.05 vs CON; †P < 0.05 vs DM
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expression changes vs. controls and other inflammatory
myopathies. Our approach differed, pre-specifying an un-
biased list of genes (the KEGG Ca2+ signaling pathway)
from which to extract transcript expression information
and perform bioinformatics analysis. This approach
allowed for detection of subtle but still highly significant
expression changes at the gene and pathway level. Our
analyses revealed the Ca2+ signaling canonical pathway to
be significantly altered in IBM, with 54 of 183 genes
(29.5%) differentially expressed vs. control muscle after
correction for multiple comparisons. Several gene expres-
sion alterations imply myocellular compensation for the
loss of Ca2+ homeostasis, such as upregulation of PVALB
(a Ca2+ buffer) and suppression of phospholamban (PLN;
a SERCA-inhibitory peptide), which would increase cyto-
solic Ca2+ buffering and SR Ca2+ uptake, respectively.
Using the upstream regulator analysis function within
IPA, which predicts activation status of upstream
molecules using a large dataset of causal experiment
data, whole-transcriptome changes observed in IBM
were determined to be highly consistent with myocel-
lular Ca2+ abundance [26].
Perhaps our most interesting finding is that IBM dis-
plays alterations in the activation status and expression
of Ca2+-activated proteases. Robust (~4-fold) elevations
in autolytic activation of the Ca2+-activated protease
calpain-1 in IBM provides strong evidence of abnormally
high cytosolic Ca2+ concentration, and may explain spe-
cific protein expression decreases (e.g. SERCA1, SERCA2,
and RyR1) that were out of proportion with their respect-
ive mRNA decreases. It is worth noting again that neither
calpain-1 transcript nor overall protein level were in-
creased in IBM, indicating that calpain-1 abnormalities in
IBM are primarily post-translational. In neurons, moder-
ate calpain-1 activation (as we observe in IBM samples)
causes cleavage of TDP-43 into aggregation-prone frag-
ments, promoting the TDP-43 cytoplasmic mislocalization
(TDP-43 proteinopathy) observed in amyotrophic lateral
sclerosis [1, 57]. As TDP-43 proteinopathy causes path-
ology in human cells by altering RNA dynamics [25, 33]
and is a specific histology finding in IBM muscle vs. other
inflammatory myopathies [23], calpain-mediated TDP-43
cleavage may reflect a highly novel upstream pathogenic
mechanism in IBM. However, no experiments have yet
confirmed that this relationship between calpain and
TDP-43 is conserved in skeletal muscle. The other Ca2
+-activated protease investigated in this study, calpain-3,
was reduced in IBM samples vs. controls and DM. This
finding is consistent with a hypothesis proposed in a pre-
vious proteomic study, in which calpain-3 substrates were
among the few over-expressed proteins in IBM samples
[43]. Contrary to calpain-1, which functions primarily
through proteolysis, calpain-3 has several important non-
proteolytic functions, including a prominent role in
sarcomere remodeling [39]. Moreover, calpain-3 was re-
cently reported to associate with and prevent proteasomal
degradation of SERCA proteins [51]. Thus, diminished
calpain-3 expression provides a novel mechanism by
which Ca2+ dysregulation may be initiated or exacerbated
and may have broader implications for myofiber adapta-
tion to damage [28, 39].
Abnormal proteostasis and downstream activation of
the UPR have long been hypothesized to contribute to
IBM pathology [55]. Supporting this theory, IBM biop-
sies have been reported to display activation of the UPR
by XBP1 splicing and elevated expression of several ER
stress-induced molecules [38, 55]. As previously dis-
cussed, the UPR suppresses translation through phos-
phorylation of eIF2α, but this had not been investigated
in IBM muscle. Consistent with previous studies, our
IBM patients displayed evidence for UPR activation, in-
cluding XBP1 induction, XBP1 mRNA splicing, and up-
regulation of the ER stress-inducible proteins BiP/
GRP78 and CHOP. As hypothesized, we also observed
increased eIF2α phosphorylation in IBM samples vs.
controls and DM, indicating that the UPR is suppressing
translation in these samples via inhibition of the eIF2α
translation initiation factor. In the context of increased
calpain-1 proteolysis and diminished expression of
calpain-3, translational attenuation in IBM muscle likely
potentiates reductions in contractile and Ca2+-regulatory
proteins. Of additional interest, activation of the UPR
can induce local inflammation, which may contribute to
repression of the gene encoding calpain-3 (CAPN3), fur-
ther linking these phenomena [19].
The relationship between Ca2+ dysregulation and other
pathogenic mechanisms in IBM is complex, but possibly
significant for disease progression. To illustrate this rela-
tionship, we propose a theoretical three-phase mechan-
ism of Ca2+ dysregulation in IBM that integrates our
data with the literature (Fig. 5). While this model does
not attempt to explain what causes an individual to de-
velop IBM, it does connect many pathological elements
observed in IBM biopsies. In the initiation [of Ca2+ dys-
regulation] phase, one or more of the following may pro-
vide an initial insult to myofiber Ca2+ homeostasis: i)
sarcolemma damage and subsequent osmotic stress stem-
ming from expanded and potentially-aggressive cytotoxic
T-lymphocytes (CTLs) [16, 20, 44]; ii) alterations in Ca2+
channel function and/or mitochondrial Ca2+ buffering due
to cytotoxic protein oligomers or fibrils [1, 11, 34, 46];
and/or iii) diminishment of SERCA function caused by
calpain-3 reduction [39, 51]. Without amelioration of such
insult(s) to Ca2+ homeostasis, Ca2+ dysregulation pro-
gresses in the propagation phase. Mitochondria, suscep-
tible to injury in IBM due to conditions of inflammation,
mtDNA abnormalities, and impaired proteostasis, are
damaged by excessive Ca2+ influx [7, 31, 32, 48]. This
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stimulates ROS production, promoting further Ca2+ efflux
from the SR [15] and ER stress signaling [32]. Cytosolic
Ca2+ elevations potentiate the activation of calpains (e.g.
calpain-1), which cleave Ca2+-regulatory proteins like
SERCA1 [49, 50]. Ca2+ and redox imbalances in the ER
perturb protein folding, inducing UPR signaling [18, 32].
Together, impairment of mitochondrial buffering, degrad-
ation of Ca2+-regulatory proteins, and suppression of
translation cause progressive increases in cytosolic Ca2+.
In the myofiber pathology phase, mitochondrial damage
has diminished the capacity for oxidative phosphorylation
through reduction of the inner mitochondrial mem-
brane potential, prolonged ER stress has altered myofi-
ber viability through induction of pro-apoptotic factors
(e.g. CHOP), and calpain-1 activation has directly con-
tributed to weakness by degrading proteins involved in
excitation-contraction coupling (e.g. RyR1).
This study provides new insights into a potential con-
tributor to IBM pathogenesis, but further research is
needed. Future studies may investigate the initiation of
Ca2+ dysregulation in IBM by interrogating the associ-
ation between indicators of Ca2+ dysregulation (e.g.
calpain-1 activation) and markers of potential upstream
causes (e.g. protein aggregation) and/or attempting to
functionally recapitulate aspects of this phenomenon
in model systems. A limitation of this study was the
use of a restricted number of biopsies, from different
patients, in immunoblot and RNA-seq studies. This
limits the strength of protein to transcript compari-
sons, although our finding of reduced protein to
transcript amongst Ca2+-regulatory proteins was well
supported by subsequent experiments (i.e. calpain-1
activation and eIF2α phosphorylation). Finally, while
we did not find substantial Ca2+-associated abnormal-
ities in our myositis control (DM) patients, future
studies may look to address whether the pathologies
of other inflammatory myopathy subsets (e.g. patients
with necrotizing myopathies or specific autoanti-
bodies) include Ca2+ dysregulation.
Conclusion
This investigation provides data, from whole-transcriptome
analysis to specific proteins alterations, that implicate Ca2+
dysregulation in the myocellular pathology of sporadic
IBM. While it is still unclear which theoretical insult(s) are
upstream of Ca2+ dysregulation in IBM, our data sug-
gest that this phenomenon is propagated by reduced
expression of calpain-3, abnormal proteolysis secondary
to calpain-1 activation, and decreased protein transla-
tion downstream of the UPR. While Ca2+ dysregulation
is unlikely to be a primary pathogenic mechanism in
IBM, it may contribute to muscle atrophy and weakness
through its pleiotropic effects on protease dynamics,
gene expression, myocellular proteostasis, and mito-
chondrial function. As such, future investigations may
investigate if targeted treatment aimed to restore Ca2+
homeostasis and/or limit the downstream effects of
prolonged Ca2+ dysregulation may be a viable thera-
peutic strategy in IBM.
Fig. 5 A theoretical mechanism of progressive Ca2+ dysregulation in IBM and downstream pathological relevance. Stage 1: An initial insult to Ca2+
regulation may come from immune-mediated membrane injury (pictured: cytotoxic T-lymphocyte), permeabilization of Ca2+ channels by abnormal
proteins, and/or reduction in calpain-3. Stage 2: Ca2+ elevations in the cytosol are then propagated through ROS production, SR Ca2+ leak, and calpain
proteolysis of Ca2+-regulatory proteins. Stage 3: Prolonged Ca2+ dyshomeostasis causes and/or exacerbates the inter-related phenomena of mitochon-
drial dysfunction, UPR signaling, protein aggregate formation, and contractile dysfunction
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Additional files
Additional file 1: Electronic Resource 1: RNA-sequencing data for genes
in the KEGG Ca2+ signaling pathway, including gene name and locus, mRNA
expression (Fragments Per Kilobase of transcript per Million mapped reads),
fold change, and comparison false discovery rate (q-value). (PDF 289 kb)
Additional file 2: Electronic Resource 2: The ratio of SERCA1 to SERCA2
protein is unaltered between groups (all P > 0.10), suggesting a lack of
fiber-type specificity in the reduction of SERCA proteins. (DOC 50 kb)
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